Evidence rulings prove crucial in Prempro cases

Two juries considering damages against Pfizer for its menopause drug Prempro reached different conclusions, and a judge's decision to keep out disputed evidence may have been the deciding factor.

This article requires free registration

This article requires free registration to Daily Business Review. Please sign in or register to read the full text.